{"title":"特发性骨肉瘤患者用trofosfamide维持治疗-单中心经验。","authors":"A. Raciborska, K. Bilska, C. Rodríguez-Galindo","doi":"10.34763/devperiodmed.20192301.3944","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nPatients with Ewing sarcoma have a dismal outcome. Maintenance treatment with trofosfamide has been proposed as an effective regimen for same paediatric malignancies.\n\n\nAIM\nWe sought to evaluate the schedule of trofosfamide for patients with high-risk primary bone Ewing sarcoma.\n\n\nMATERIALS AND METHODS\nFifteen patients with primary bone Ewing sarcoma received treatment with trofosfamide (750 mg/m2 p.o. days 1-10) every 28 days. All patients hod standard tumour imaging and laboratory evaluation. All toxicities were documented.\n\n\nRESULTS\nA tatal of 90 cycles (median 5 cycles/patient) were administered. A complete response was maintained in nine patients, while six patients had disease progression during treatment Median time to progression was 7.9 months (range 1.8 to 4.6). Eleven patients (73.3%) are alive including nine with no evidence of disease with a median follow-up of 3.9 years (range 7.4 to 7.6). All patients with active disease at the start of the trofosfamide treatment died. There were no significant toxicities.\n\n\nCONCLUSIONS\nTreatment with trofosfamide is well-tolerated and could have a role to maintain response in patients with primary bone Ewing sarcoma. Further studies are needed to better define the use of this regimen in the upfrront management of those patients.","PeriodicalId":35058,"journal":{"name":"Medycyna wieku rozwojowego","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Maintenance treatment with trofosfamide in patients with primary bone ewing sarcoma - single center experience.\",\"authors\":\"A. Raciborska, K. Bilska, C. Rodríguez-Galindo\",\"doi\":\"10.34763/devperiodmed.20192301.3944\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND\\nPatients with Ewing sarcoma have a dismal outcome. Maintenance treatment with trofosfamide has been proposed as an effective regimen for same paediatric malignancies.\\n\\n\\nAIM\\nWe sought to evaluate the schedule of trofosfamide for patients with high-risk primary bone Ewing sarcoma.\\n\\n\\nMATERIALS AND METHODS\\nFifteen patients with primary bone Ewing sarcoma received treatment with trofosfamide (750 mg/m2 p.o. days 1-10) every 28 days. All patients hod standard tumour imaging and laboratory evaluation. All toxicities were documented.\\n\\n\\nRESULTS\\nA tatal of 90 cycles (median 5 cycles/patient) were administered. A complete response was maintained in nine patients, while six patients had disease progression during treatment Median time to progression was 7.9 months (range 1.8 to 4.6). Eleven patients (73.3%) are alive including nine with no evidence of disease with a median follow-up of 3.9 years (range 7.4 to 7.6). All patients with active disease at the start of the trofosfamide treatment died. There were no significant toxicities.\\n\\n\\nCONCLUSIONS\\nTreatment with trofosfamide is well-tolerated and could have a role to maintain response in patients with primary bone Ewing sarcoma. Further studies are needed to better define the use of this regimen in the upfrront management of those patients.\",\"PeriodicalId\":35058,\"journal\":{\"name\":\"Medycyna wieku rozwojowego\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medycyna wieku rozwojowego\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34763/devperiodmed.20192301.3944\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medycyna wieku rozwojowego","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34763/devperiodmed.20192301.3944","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Maintenance treatment with trofosfamide in patients with primary bone ewing sarcoma - single center experience.
BACKGROUND
Patients with Ewing sarcoma have a dismal outcome. Maintenance treatment with trofosfamide has been proposed as an effective regimen for same paediatric malignancies.
AIM
We sought to evaluate the schedule of trofosfamide for patients with high-risk primary bone Ewing sarcoma.
MATERIALS AND METHODS
Fifteen patients with primary bone Ewing sarcoma received treatment with trofosfamide (750 mg/m2 p.o. days 1-10) every 28 days. All patients hod standard tumour imaging and laboratory evaluation. All toxicities were documented.
RESULTS
A tatal of 90 cycles (median 5 cycles/patient) were administered. A complete response was maintained in nine patients, while six patients had disease progression during treatment Median time to progression was 7.9 months (range 1.8 to 4.6). Eleven patients (73.3%) are alive including nine with no evidence of disease with a median follow-up of 3.9 years (range 7.4 to 7.6). All patients with active disease at the start of the trofosfamide treatment died. There were no significant toxicities.
CONCLUSIONS
Treatment with trofosfamide is well-tolerated and could have a role to maintain response in patients with primary bone Ewing sarcoma. Further studies are needed to better define the use of this regimen in the upfrront management of those patients.